Cargando…
Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report
Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy, but has rarely been reported following anti-programmed death ligand-1 therapy. We report the case of a 55-year-old man with metastatic lung adenocarcinoma who presente...
Autores principales: | Sackstein, Paul, Zaemes, Jacob, Kim, Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327834/ https://www.ncbi.nlm.nih.gov/pubmed/34330765 http://dx.doi.org/10.1136/jitc-2021-002855 |
Ejemplares similares
-
Cytokine release syndrome induced by pembrolizumab: A case report
por: Zhang, Xinyu, et al.
Publicado: (2022) -
Pembrolizumab: Cytokine release syndrome and haemophagocytic lymphohistiocytosis : case report
Publicado: (2021) -
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021) -
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
por: Baek, Dong Won, et al.
Publicado: (2021) -
Beyond the Expectation: Pembrolizumab-Associated Tumor Lysis Syndrome in Metastatic Gastric Adenocarcinoma
por: Battah, Arwa, et al.
Publicado: (2023)